Gattex - Takeda Pharmaceuticals USA, Inc.
- Manufacturer
- Takeda Pharmaceuticals USA, Inc.
- Effective date
- 2025-08-13
- Label type
- Risk Evaluation & Mitigation Strategies
- Version
- 5
- Source
- full-release
- Hydrated at
- 2026-06-04 22:50:42
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
I. Administrative Information
Risk(s): Possible acceleration of neoplastic growth and enhancement of gastric, small intestinal (duodenum, ileum, and jejunum), and colon polyp growth, gastrointestinal obstruction, and biliary and pancreatic disorders
Application Number: NDA 203441
Application Holder: Takeda Pharmaceuticals U.S.A, Inc.
Initial REMS Approval: 12/2012
Most Recent REMS Update: 08/2025
II. REMS Goals
The goals of the GATTEX REMS are to mitigate the risks of possible acceleration of neoplastic growth and enhancement of gastric, small intestinal (duodenum, ileum, and jejunum), and colon polyp growth, gastrointestinal obstruction, and biliary and pancreatic disorders associated with GATTEX by:
- Informing patients about the risks listed above associated with the use of GATTEX
- Informing healthcare providers about the risks listed above associated with GATTEX
III. REMS Requirements
Takeda Pharmaceuticals U.S.A, Inc. must provide training to healthcare providers who prescribe GATTEX
The training includes the following educational materials: Prescribing Information, Medication Guide, Dear Healthcare Professional Letter, Prescriber Education Slide Deck, Post-Training Knowledge Assessment Questions, and Patient and Caregiver Counseling Guide. The training must be available online via the REMS website
www.GATTEXREMS.com, by calling the REMS Program Call Center, during prescriber visits by Takeda representatives, at professional society meetings, and at medical educational venues where Takeda has a presence. In addition, the Prescriber Education Slide Deck must be part of training/educational programs provided by medical science liaisons.
REMS APPLICANT REQUIREMENTS
| Target Audience | Communication Materials & Dissemination Plans |
|---|---|
| Healthcare providers who are likely to prescribe GATTEX | REMS Letter: Dear Healthcare Professional Letter with attachment: Prescriber Education Slide Deck
|
To support REMS Program operations, Takeda Pharmaceuticals U.S.A, Inc. must:
- Establish and maintain a REMS Program website,
www.GATTEXREMS.com. The REMS Program website must include the capability to complete prescriber training online, and the option to print the Prescribing Information, Medication Guide, and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS Program website. The REMS Program website must not link back to the promotional product website(s). - Make the REMS Program website fully operational and all REMS materials available through the REMS website and REMS call center within 60 calendar days of REMS modification.
- Establish and maintain a REMS Program call center for REMS participants at 1-855-5GATTEX (1-855-542-8839).
- Establish and maintain a validated, secure database of all healthcare providers who have completed training for the GATTEX REMS Program.
- Ensure healthcare providers are able to report completion of training by fax at 1-855-359-3393 and online.
IV. REMS Assessment Timetable
Takeda Pharmaceuticals U.S.A, Inc. must submit REMS Assessments at 12 months from the date of the initial REMS (12/21/2012) and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Takeda Pharmaceuticals U.S.A, Inc. must submit each assessment so that it will be received by the FDA on or before the due date.
V. REMS Materials
The following materials are part of the GATTEX REMS:
Training and Educational Materials
- Prescriber:
- Prescriber Education Slide Deck
- Dear Healthcare Professional Letter
- Post-Training Knowledge Assessment Questions
- Patient:
- Patient and Caregiver Counseling Guide
Other Materials
VI. Statutory Elements
This REMS is required under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21U.S.C. 355-1) and consists of the following elements:
- Elements to Assure Safe Use (ETASU):
- Healthcare providers who prescribe Gattex (teduglutide) are provided training under 505-1(f)(3)(A)
- Timetable for Submission of Assessments
DailyMed REMS / Drug Safety Documents#
Labels related to this REMS document
| DailyMed label | Relation | Version | Effective | Manufacturer | Source |
|---|---|---|---|---|---|
| These highlights do not include all the information needed to use GATTEX safely and effectively. See full prescribing information for GATTEX. GATTEX ® (teduglutide) for injection, for subcutaneous use Initial U.S. Approval: 2012 | SPL related document | 2025-09-05 | Takeda Pharmaceuticals America, Inc. | 20250925_12e6b789-7c0f-43dc-a988-03f45527d50e.zip!2f6574b7-4776-47c2-8819-c6ca411e4e87.xml |
Products#
Every source-derived product name is available through these pages.
- Gattex
- teduglutide
- Takeda Pharmaceuticals America, Inc.
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gattex | TEDUGLUTIDE | Takeda Pharmaceuticals America, Inc. | 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa | 2025-09-05 | Warnings, Adverse reactions | Gattex |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.